SCHEMBL18555403

SCHEMBL18555403

COc1ccc(Cn2c(=O)n(CC(=O)O)c3ccc(C#C[Si](C)(C)C)cc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.44
WDR77 Q9BQA1 1/20 0.44
CCR2 P41597 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.39
TBXA2R P21731 2/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.39
MMP13 P45452 1/20 0.39
RGS12 O14924 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18555694 0.85 PRMT5 (0.46) PRMT5WDR77CCR2MEN1KMT2A
SCHEMBL18555481 0.84 FFAR1 (0.43) PRMT5WDR77CCR2MEN1KMT2A
SCHEMBL18555697 0.80 PTGS2 (0.52) CCR2MEN1KMT2APDE1B
SCHEMBL11257792 0.79 MEN1 (0.64) MEN1KMT2AMAPTTBXA2RPTGDR2
SCHEMBL18180375 0.75 APEX1 (0.57)
SCHEMBL11262469 0.72 TSHR (0.63) KMT2AMAPTALDH1A1TSHR
SCHEMBL10487857 0.70 MAPT (0.64) MEN1KMT2AMAPT
SCHEMBL21382755 0.69 PRMT5 (0.55) PRMT5WDR77MEN1KMT2AMAPT
SCHEMBL11481174 0.69 APEX1 (0.60) MEN1KMT2AMAPTPTGDR2ALDH1A1
SCHEMBL24093939 0.67 MEN1 (0.44) PRMT5WDR77CCR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017035415-A1 ALKYNE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-03-02 WO disclosed